IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

luspatercept-aamt for injection

luspatercept-aamt for injection
for subcutaneous use Initial U.S. Approval:  2019

Reblozyl (luspatercept) is a medication used for the treatment of adults with anemia (low red blood cells) associated with beta thalassemia or myelodysplastic syndromes.

Facts about luspatercept-aamt for injection

Dosage Forms and Strengths:  For injection: 25 mg lyophilized powder in a single-dose vial for reconstitution (3) For injection: 75 mg lyophilized powder in a single-dose vial for reconstitution.
MANUFACTURER-Bristol-Myers Squibb
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “luspatercept-aamt for injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For luspatercept-aamt for injection

Approved accessible "luspatercept-aamt for injection"

Luspatercept, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. Luspatercept is indicated for the treatment of adults with transfusion-dependent anaemia associated with beta thalassaemia.

How can 1 go about obtaining luspatercept-aamt for injection?

To access luspatercept-aamt for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Reblozyl (luspatercept-aamt for injection) for subcutaneous use Initial U.S. Approval:  2019

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398